The efficacy and safety of albumin-bound paclitaxel in more than the third-line chemotherapy for advanced malignance
10.3760/cma.j.issn.1006-9801.2014.08.010
- VernacularTitle:白蛋白结合型紫杉醇在晚期恶性肿瘤三线及以上化疗中的效果及安全性
- Author:
Yijun WANG
;
Lijing GAN
;
Shen XU
- Publication Type:Journal Article
- Keywords:
Albumin-bound paclitaxel;
Advanced malignance;
The third-line chemotherapy;
Efficacy;
Safety
- From:
Cancer Research and Clinic
2014;26(8):541-543
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the efficacy and safety of albumin-bound paclitaxel on the patients with advanced malignance in more than the third-lines (including the third-lines).Methods 34 patients with advanced malignance diagnosed by pathological evidence accepted more than the third-lines (including the third-lines) chemotherapy containing albumin-bound paclitaxel after failure of chemotherapy.The efficacy and safety were observed.Results Totally 110 cycles chemotherapy were completed,with a mean of 3.24 cycles in each of the 34 patients.No CR patients,12 cases of PR,9 cases of SD and 13 cases of PD were found.The response rate (RR) was 35.29 ％ (12/34) and the disease control rate (DCR) was 61.76 ％ (21/34).The main toxicity was hematologic toxicity,including neutropenia in 26 cases (76.47 ％),anemia in 14 cases (41.18 ％) and thrombocytopenia in 3 cases (8.82 ％).Other common adverse reactions included alopecia in 27 patients (79.41％) and muscle and joint pain in 15 cases (44.18 ％).Conclusions The albumin-bound paclitaxel is effective and tolerable in patients with advanced malignance in more than the third-lines (include the thirdlines) chemotherapy.
